NewHydrogen (NEWH) 10-K/A 20 Mar 18 2017 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 12, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BioSolar Inc
Entity Central Index Key	1,371,128
Trading Symbol	BSRC
Amendment Flag	true
Amendment Description	EXPLANATORY NOTE BioSolar, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A (the “Form 10-K/A”) to its Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 19, 2018 (the “Form 10-K”), solely to update the Report of Independent Registered Public Accounting Firm (the “Report”), filed with the financial statements to the Form 10-K. The Report was filed incorrectly due solely to administrative error. In connection with the filing of this Form 10-K/A and pursuant to the rules of the SEC, we are including with this Form 10-K/A certain new certifications by our principal executive officer and acting principal financial officer. Accordingly, Part II, Item 8 of the Form 10-K is being amended to include the updated Report and Part IV, Item 15 of the Form 10-K is being amended to reflect the filing of the new certifications. Other than with respect to the foregoing, this Form 10-K/A does not modify or update in any way the disclosures made in the Form 10-K, including the disclosures contained in Part I, Part II (Items 5 through 7 and Items 9 through 9B) and Part III of the Form 10-K. This Form 10-K/A speaks as of the original filing date of the Form 10-K and does not reflect events that may have occurred subsequent to such original filing date.
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 1,519,382
Entity Common Stock, Shares Outstanding		46,508,334

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 119,446	$ 208,629
Prepaid expenses	21,644	22,265
TOTAL CURRENT ASSETS	141,090	230,894
PROPERTY AND EQUIPMENT
Machinery and equipment	31,455	31,455
Less accumulated depreciation	(23,733)	(20,411)
NET PROPERTY AND EQUIPMENT	7,722	11,044
OTHER ASSETS
Patents, net of amortization of $6,045 and $0, respectively	69,442	74,787
Deposit	770	770
TOTAL OTHER ASSETS	70,212	75,557
TOTAL ASSETS	219,024	317,495
CURRENT LIABILITIES
Accounts payable	31,845	16,758
Accrued expenses	414,702	236,170
Derivative liability	5,239,073	5,044,897
Convertible promissory notes net of debt discount of $5,340 and $100,320, respectively	396,660	329,680
TOTAL CURRENT LIABILITIES	6,082,280	5,627,505
LONG TERM LIABILITIES
Convertible promissory notes net of debt discount of $351 and $35,810, respectively	1,791,279	1,334,190
TOTAL LONG TERM LIABILITIES	1,791,279	1,334,190
TOTAL LIABILITIES	7,873,559	6,961,695
SHAREHOLDERS' DEFICIT
Preferred stock, $0.0001 par value; 10,000,000 authorized common shares
Common stock, $0.0001 par value; 500,000,000 authorized common shares 41,485,051 and 29,519,405 shares issued and outstanding, respectively	4,149	2,952
Additional paid in capital	11,127,693	9,354,201
Accumulated deficit	(18,786,377)	(16,001,353)
TOTAL SHAREHOLDERS' DECIFIT	(7,654,535)	(6,644,200)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 219,024	$ 317,495

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Patents, net of amortization	$ 6,045	$ 0
Convertible promissory notes net of debt discount, current	5,340	100,320
Convertible promissory notes net of debt discount, non current	$ 351	$ 35,810
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	41,485,051	29,519,405
Common stock, shares outstanding	41,485,051	29,519,405

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
REVENUE
OPERATING EXPENSES
General and administrative expenses	1,663,058	2,095,438
Research and development	176,306	226,881
Depreciation and amortization	9,368	3,085
TOTAL OPERATING EXPENSES	1,848,732	2,325,404
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES)	(1,848,732)	(2,325,404)
TOTAL OTHER INCOME/(EXPENSES)
Interest income	39	59
Gain (Loss) on conversion of debt and change in derivative liability	(586,481)	3,134,813
Interest expense	(349,850)	(609,669)
TOTAL OTHER (EXPENSES) INCOME	(936,292)	2,525,203
(LOSS) INCOME BEFORE PROVISION FOR INCOME TAXES	(2,785,024)	199,799
Provision for income taxes
NET (LOSS) INCOME	$ (2,785,024)	$ 199,799
BASIC (LOSS) EARNINGS PER SHARE	$ (0.08)	$ 0.01
DILUTED (LOSS) EARNINGS PER SHARE	$ (0.08)	$ 0.01
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC	35,784,211	22,971,319
DILUTED	35,784,211	39,096,319

Statement of Shareholders' Defi

Statement of Shareholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2015		$ 1,799	$ 7,474,644	$ (16,201,152)	$ (8,724,709)
Balance, shares at Dec. 31, 2015		17,995,953
Issuance of common shares for converted promissory notes and accrued interest		$ 844	101,590		102,434
Issuance of common shares for converted promissory notes and accrued interest, shares		8,437,636
Issuance of common shares for related party converted promissory notes and accrued interest		$ 309	206,198		206,507
Issuance of common shares for related party converted promissory notes and accrued interest, shares		3,085,816
Stock based compensation			1,571,769		1,571,769
Net Income/Loss for the year				199,799	199,799
Balance at Dec. 31, 2016		$ 2,952	9,354,201	(16,001,353)	(6,644,200)
Balance, shares at Dec. 31, 2016		29,519,405
Issuance of common shares for converted promissory notes and accrued interest		$ 1,197	508,256		509,453
Issuance of common shares for converted promissory notes and accrued interest, shares		11,965,646
Stock based compensation			1,265,236		1,265,236
Net Income/Loss for the year				(2,785,024)	(2,785,024)
Balance at Dec. 31, 2017		$ 4,149	$ 11,127,693	$ (18,786,377)	$ (7,654,535)
Balance, shares at Dec. 31, 2017		41,485,051

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (Loss) Income	$ (2,785,024)	$ 199,799
Adjustment to reconcile net (loss) income to net cash used in operating activities
Depreciation and amortization expense	9,368	3,085
Stock based compensation	1,265,236	1,571,769
(Gain) Loss on net change in derivative liability and conversion of debt	586,481	(3,134,813)
Amortization of debt discount recognized as interest expense	146,279	443,979
(Increase) Decrease in Changes in Assets
Prepaid expenses	621	64,678
Increase (Decrease) in Changes in Liabilities
Accounts payable	15,087	14,703
Accrued expenses	201,469	164,936
NET CASH USED IN OPERATING ACTIVITIES	(560,483)	(671,864)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment		(2,600)
Patent expenditures	(700)	(4,517)
NET CASH USED IN INVESTING ACTIVITIES	(700)	(7,117)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes	472,000	685,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	472,000	685,000
NET (DECREASE) INCREASE IN CASH	(89,183)	6,019
CASH, BEGINNING OF YEAR	208,629	202,610
CASH, END OF YEAR	119,446	208,629
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	1,974	880
Taxes paid
SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS
Common stock issued for convertible notes and accrued interest	509,453	102,434
Common stock issued for related party convertible notes and accrued interest		$ 206,507

Organization and Line of Busine

Organization and Line of Business	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND LINE OF BUSINESS	1. ORGANIZATION AND LINE OF BUSINESS Organization BioSolar, Inc. (the "Company") was incorporated in the state of Nevada on April 24, 2006. The Company, based in Santa Clarita, California, began operations on April 25, 2006 to develop and market Photovoltaic solar technology products. Line of Business We are engaged in the development of innovative technologies and materials that will reduce the cost per watt of storing electrical energy. We previously developed BioBacksheet R Going Concern The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. During the year ended December 31, 2017, the Company did not generate any revenue, incurred a net loss of $2,785,024 and used cash in operations of $560,483. As of December 31, 2017, the Company had a working capital deficiency of $5,941,190 and a shareholders’ deficit of $7,654,535. These factors, among others raise substantial doubt about the Company’s ability to continue as a going concern. Our independent auditors, in their report on our audited financial statements for the year ended December 31, 2017 expressed substantial doubt about our ability to continue as a going concern. The accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, achieving a level of profitable operations and receiving additional cash infusions. During the year ended December 31, 2017, the Company obtained funds from the issuance of convertible note agreements. Management believes this funding will continue from its’ current investors and from new investors. Management believes the existing shareholders, and the prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due, and will allow the development of its core business operations. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, the Company has not had significant revenues and is in the development stage. Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates. Research and Development Research and development costs are expensed as incurred. Total research and development costs were $176,306 and $226,881 for the years ended December 31, 2017 and 2016, respectively. Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. During the years ended December 31, 2017 and 2016, the Company reviewed the capitalized patents for impairment in accordance with ASC 350, and determined there was no impairment. Intangible assets that have finite useful lives continue to be amortized over their useful lives Useful Lives 2017 2016 Patents $ 75,487 $ 74,787 Less accumulated amortization 15 years (6,045 ) - $ 69,442 $ 74,787 The Company recognized amortization expense of $6,045 and $0 for the years ended December 31, 2017 and 2016. Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: Computer equipment 5 Years Machinery and equipment 10 Years Depreciation expense for the years ended December 31, 2017 and 2016 was $3,323 and $3,085, respectively. Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company uses the Black Scholes pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. On March 24, 2015, the Company granted 2,450,000 stock options with an exercise price of $0.09 per share, and on September 2, 2015 the Company granted an additional 13,500,000 stock options with an exercise price of $0.26 per share. The options will vest 1/25 on monthly basis, starting April 24, 2015 and October 1, 2015, respectively, and terminate seven (7) years from the date of grant or upon termination of employment. Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).     For the year ended December 31, 2017, the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company excluded 15,975,000 stock options, and the shares issuable from the convertible debt of $2,193,630, because their impact was antidilutive.  For the year ended December 31, 2016, the Company calculated the dilutive impact of the outstanding stock options of 1,650,000, warrants of 150,000, and the convertible debt of $1,800,000, which is convertible into shares of common stock. The stock options and warrants were included in the calculation of net earnings per share, because their impact was dilutive.  For the years ended December 31, 2017 2016 Income (Loss) to common shareholders (Numerator) $ (2,785,024 ) $ 199,799 Basic weighted average number of common shares outstanding (Denominator) 35,784,211 22,971,319 Diluted weighted average number of common shares outstanding (Denominator) 35,784,211 39,096,319 Fair Value of Financial Instruments Fair Value of Financial Instruments, requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2017, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2017 and 2016: Total (Level 1) (Level 2) (Level 3) Derivative Liability Total Liabilities measured at fair value as of December 31, 2017 $ 5,239,073 $ - $ - $ 5,239,073 Total Liabilities measured at fair value as of December 31, 2016 $ 5,044,897 $ - $ - $ 5,044,897 The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: Balance as of January 1, 2016 $ 7,878,599 Fair value of derivative liabilities issued 301,111 Loss on conversion of debt and change in derivative liability (3,134,813 ) Balance as of December 31, 2016 $ 5,044,897 Fair value of derivative liabilities issued 15,840 Gain on conversion of debt and change in derivative liability 173,338 Balance as of December 31, 2017 $ 5,239,073 Recently Issued Accounting Pronouncements In May 2017, FASB issued accounting standards update ASU-2017-09, “Compensation-Stock Compensation” (Topic 718) –Modification Accounting”, to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this ASU are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period for public entities for reporting periods for which financial statements have not yet been issued, and all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company is currently evaluating the impact of the adoption of ASU 2017-09 on the Company’s financial statements. In August 2017, FASB issued accounting standards update ASU-2017-12, “D” (Topic 815) – “Targeted Improvements to Accounting for Hedging Activities”, to require an entity to present the earnings effect of the hedging instrument in the same statement line item in which the earnings effect of the hedged item is reported. The amendments in this update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods with the fiscal years beginning after December 15, 2020. Early adoption is permitted in any interim period after issuance of the update. The Company is currently evaluating the impact of the adoption of ASU 2017-12 on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
CAPITAL STOCK	3. CAPITAL STOCK During the year ended December 31, 2017, the Company issued 11,965,646 shares of common stock upon conversion of convertible promissory notes in the amount of $78,370, plus accrued interest of $22,939, with an aggregate fair value loss of $408,144 at prices ranging from $0.0350 and $0.0549 per share upon conversion During the year ended December 31, 2016, the Company issued 8,437,636 shares of common stock at prices of $0.00847 and $0.01333 per share upon conversion of $84,500 in convertible promissory notes, including $17,934 in accrued interest and issued 3,085,816 shares of common stock at a price of $0.056 to $0.115 per share upon conversion of related party convertible promissory notes with a fair value of $185,000, plus accrued interest of $21,507.

Stock Options and Warrants

Stock Options and Warrants	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK OPTIONS AND WARRANTS	4. STOCK OPTIONS AND WARRANTS Stock Options The Company did not grant any stock options during the years ended December 31, 2017 and 2016, respectively. 2017 2016 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the years 15,975,000 $ 0.23 15,978,333 $ 0.23 Granted - $ - - $ - Exercised - $ - - $ - Expired - $ - (3,333 ) $ 4.05 Outstanding as of the end of the years 15,975,000 $ 0.23 15,975,000 $ 0.23 Exercisable as of the end of the years 15,975,000 $ 0.23 10,183,000 $ 0.21 The weighted average remaining contractual life of options outstanding as of December 31, 2017 and 2016 was as follows: 12/31/2017 12/31/2016 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.40 25,000 25,000 0.16 $ 0.40 25,000 25,000 1.17 $ 0.09 2,450,000 2,450,000 4.23 $ 0.09 2,450,000 2,058,000 5.23 $ 0.26 13,500,000 13,500,000 4.67 $ 0.26 13,500,000 8,100,000 5.70 15,975,000 15,975,000 15,975,000 10,183,000 Stock Options The stock-based compensation expense recognized in the statement of operations during the years ended December 31, 2017 and 2016, related to the granting of these options was $1,265,236 and $1,571,769, respectively. As of December 31, 2017, there was no intrinsic value with regards to the outstanding options. Warrants During the year ended December 31, 2017, 150,000 purchase warrants expired in October 2017. The Company granted no warrants during the year ended December 31, 2017. The were no warrants outstanding as of December 31, 2017. 2017 2016 Number of Warrants Weighted average exercise price Number of Warrants Weighted average exercise price Outstanding as of the beginning of the years $ 150,000 $ 0.55 $ 245,000 $ 0.97 Granted - - - Exercised - - - Expired (150,000 ) $ 0.55 $ (95,000 ) $ 1.80 Outstanding as of the end of the years $ - $ - $ 150,000 $ 0.55 Exercisable at the end of years $ - $ - $ 150,000 $ 0.55

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES	5. CONVERTIBLE PROMISSORY NOTES As of December 31, 2017, the outstanding convertible promissory notes are summarized as follows: Convertible Promissory Notes, net of debt discount $ 2,187,939 Less current portion 396,660 Total long-term liabilities $ 1,791,279 Maturities of long-term debt for the next three years are as follows: Year Ending December 31, Amount 2019 $ 306,630 2020 730,000 2021 754,649 $ 1,791,279 At December 31, 2017, the $2,193,630 in convertible promissory notes had a remaining debt discount of $5,691, leaving a net balance of $2,187,939. On May 2, 2014, the Company entered into a securities purchase agreement, providing for the sale by the Company of a 10% unsecured convertible note (the “May Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received a tranche in the amount of $50,000. On various dates, the Company received additional tranches in the aggregate sum of $450,000, for a total aggregate sum of $500,000. As of December 31, 2015, the remaining principal balance was $467,500. During the year ended December 31, 2017, the Company issued 11,965,646 shares of common stock for principal in the amount of $78,370, plus accrued interest of $22,939, leaving a principal balance of $306,630. Each tranche matures eighteen (18) months from the effective date of each tranche, which was extended on January 12, 2016 to sixty (60) months, with maturity dates ranging from June 12, 2019 to December 21, 2019. The May Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. The fair value of the May Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche. On January 30, 2015, the Company entered into a securities purchase agreement, providing for the sale by the Company of a 10% unsecured convertible note (the “January Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received a tranche in the amount of $50,000. On various dates, the Company received additional tranches in the aggregate sum of $450,000. The principal balance at December 31, 2017 was $500,000. Each tranche matured eighteen (18) months from the effective date of each tranche, which was extended on January 12, 2016 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from January 29, 2020 to August 25, 2020. The January Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.15 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the January Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the January Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $25,898 during the year ended December 31, 2017. On October 1, 2015, the Company entered into a securities purchase agreement, providing for the sale by the Company of a 10% unsecured convertible note (the “October Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received a tranche in the amount of $90,000. On various dates, the Company received additional tranches in the aggregate sum of $395,000. The principal balance at December 31, 2017 was $485,000. Each tranche matures twelve (12) months from the effective date of each tranche, which was extended on October 13, 2016 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from October 1, 2020 to March 9, 2021. The October Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the October Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the October Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $9,912 during the year ended December 31, 2017. On April 5, 2016, the Company entered into a securities purchase agreement, providing for the sale by the Company of a 10% unsecured convertible note (the “April Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received a tranche in the amount of $48,000. On various dates, the Company received additional tranches in the aggregate sum of $452,000. The principal balance at December 31, 2017 was $500,000. Each tranche matures twelve (12) months from the effective date of each tranche through November 15, 2017. The April Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the April Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the April Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $104,524 during the year ended December 31, 2017. On March 20, 2017, the Company entered into a securities purchase agreement, providing for the sale by the Company of a 10% unsecured convertible note (the “March Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the securities purchase agreement, the Company received a tranche in the amount of $25,000. On various dates during the year ended December 31, 2017, the Company received additional tranches in the aggregate sum of $377,000. The principal balance as of December 31, 2017 was $402,000. Each tranche matures twelve (12) months from the effective date of each tranche, with an extension of sixty (60) months from each tranche. The March Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the March Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the March Note has been determined by using the Binomial lattice formula with an expected life of twelve (12) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $5,945 during the year ended December 31, 2017.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	6. DERIVATIVE LIABILITIES We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations. The convertible notes issued and described in Note 5 do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. During the year ended December 31, 2017, as a result of the convertible notes (“Notes”) issued that were accounted for as derivative liabilities, we determined that the fair value of the conversion feature of the convertible notes at issuance was $15,840, based upon a Binomial-Model calculation. We recorded the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the Notes. During the year ended December 31, 2017, the Company converted $78,370 in principal of convertible notes, plus accrued interest of $22,939. As a result of the conversion of these notes and the change in fair value of the remaining notes, the Company recorded a loss on net change in derivative and conversion of debt in the amount of $586,481 in the statement of operations for the year ended December 31, 2017. At December 31, 2017, the fair value of the derivative liability was $5,239,073. For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation model for the derivative are as follows: 12/31/2017 Risk free interest rate 1.39% - 2.20 % Stock volatility factor 74.0% - 136 % Weighted average expected option life 1 years - 5 years Expected dividend yield None

Deferred Taxes

Deferred Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
DEFERRED TAXES	7. DEFERRED TAXES The Company files income tax returns in the U.S. Federal jurisdiction, and the state of California. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before 2015. Deferred income taxes have been provided by temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for tax purposes. To the extent allowed by GAAP, we provide valuation allowances against the deferred tax assets for amount when the realization is uncertain. Included in the balance at December 31, 2017 and 2016, are no tax positions for which the ultimate deductibility is highly certain, but for which there is uncertainty about the timing of such deductibility. Because of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period. The Company's policy is to recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. During the periods ended December 31, 2017 and 2016, the Company did not recognize interest or penalties. At December 31, 2017, the Company had net operating loss carry-forwards of approximately $7,925,000, which expires 20 years after the NOL year. No tax benefit has been reported in the December 31, 2017 and 2016 financial statements, since the potential tax benefit is offset by a valuation allowance of the same amount. The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the years ended December 31, 2017 and 2016 due to the following: 2017 2016 Book income (loss) $ (1,114,010 ) $ 79,830 Depreciation 680 (1,590 ) Meals and entertainment 240 160 Non-deductible non-cash charges 879,830 (380,530 ) Valuation Allowance 233,260 302,130 Income tax expense $ - $ - Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the difference between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net deferred tax liabilities consist of the following components as of December 31, 2017 and 2016: 2017 2016 Deferred tax assets: NOL carryover $ (3,170,060 ) $ (2,947,120 ) R & D credit 91,630 87,480 Depreciation 10,740 10,740 Deferred tax liabilites: Depreciation - - Less Valuation Allowance 3,067,690 2,848,900 Net deferred tax asset $ - $ - Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry-forwards for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry-forwards may be limited as to use in future years. The Company’s tax returns for the previous three years remain open for audit by the respective tax jurisdictions.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT AND CONTINGENCIES	8. COMMIMENT AND CONTINGENCIES On October 2, 2017, the Company amended its lease for office space by extending the lease to October 31, 2018. During the year ended December 31, 2017, we have a new material commitment for capital expenditures in the form of a sponsored research agreement with North Carolina Agricultural and Technical State University during the next twelve months. On August 24, 2017, the Company extended its contract for a period of September 12, 2017 through September 11, 2018, and the total cost shall not exceed the sum of $159,610. The commitment is financed by the issuance of equity or debt securities of the Company.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS Management has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has determined that there are the following subsequent events: In January and February 2018, the Company received two tranches for an aggregate amount of $98,000 pursuant to the securities purchase agreement entered into on March 20, 2017. The securities purchase agreement provided for the issuance of the March Note in the aggregate principal amount of up to $500,000. The March Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded on any trade day after the effective date or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. During the month of January and February 2018, the Company issued 5,023,283 shares of common stock upon conversion of a convertible promissory note for principal in the amount of $28,190, plus accrued interest of $9,734. On February 26, 2018, the Company received $15,000 in consideration upon the execution of a securities purchase agreement for the issuance of a 10% unsecured convertible note (“February Note”) in the aggregate principal amount of up to $500,000. The February Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.03 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded on any trade day after the effective date or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, the Company has not had significant revenues and is in the development stage.
Cash and Cash Equivalent	Cash and Cash Equivalent The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates.
Research and Development	Research and Development Research and development costs are expensed as incurred. Total research and development costs were $176,306 and $226,881 for the years ended December 31, 2017 and 2016, respectively.
Intangible Assets	Intangible Assets The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. During the years ended December 31, 2017 and 2016, the Company reviewed the capitalized patents for impairment in accordance with ASC 350, and determined there was no impairment. Intangible assets that have finite useful lives continue to be amortized over their useful lives Useful Lives 2017 2016 Patents $ 75,487 $ 74,787 Less accumulated amortization 15 years (6,045 ) - $ 69,442 $ 74,787 The Company recognized amortization expense of $6,045 and $0 for the years ended December 31, 2017 and 2016.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, and are depreciated using straight line over its estimated useful lives: Computer equipment 5 Years Machinery and equipment 10 Years Depreciation expense for the years ended December 31, 2017 and 2016 was $3,323 and $3,085, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period. Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility. The Company uses the Black Scholes pricing model to value its stock option awards which incorporate the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. On March 24, 2015, the Company granted 2,450,000 stock options with an exercise price of $0.09 per share, and on September 2, 2015 the Company granted an additional 13,500,000 stock options with an exercise price of $0.26 per share. The options will vest 1/25 on monthly basis, starting April 24, 2015 and October 1, 2015, respectively, and terminate seven (7) years from the date of grant or upon termination of employment.
Income Taxes	Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
Net Earnings (Loss) per Share Calculations	Net Earnings (Loss) per Share Calculations Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).     For the year ended December 31, 2017, the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company excluded 15,975,000 stock options, and the shares issuable from the convertible debt of $2,193,630, because their impact was antidilutive.  For the year ended December 31, 2016, the Company calculated the dilutive impact of the outstanding stock options of 1,650,000, warrants of 150,000, and the convertible debt of $1,800,000, which is convertible into shares of common stock. The stock options and warrants were included in the calculation of net earnings per share, because their impact was dilutive.  For the years ended December 31, 2017 2016 Income (Loss) to common shareholders (Numerator) $ (2,925,137 ) $ 199,799 Basic weighted average number of common shares outstanding (Denominator) 35,784,211 22,971,319 Diluted weighted average number of common shares outstanding (Denominator) 35,784,211 39,096,319
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value of Financial Instruments, requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2017, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2017 and 2016: Total (Level 1) (Level 2) (Level 3) Derivative Liability Total Liabilities measured at fair value as of December 31, 2017 $ 5,239,073 $ - $ - $ 5,239,073 Total Liabilities measured at fair value as of December 31, 2016 $ 5,044,897 $ - $ - $ 5,044,897 The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value: Balance as of January 1, 2016 $ 7,878,599 Fair value of derivative liabilities issued 301,111 Loss on conversion of debt and change in derivative liability (3,134,813 ) Balance as of December 31, 2016 $ 5,044,897 Fair value of derivative liabilities issued 15,840 Gain on conversion of debt and change in derivative liability 173,338 Balance as of December 31, 2017 $ 5,239,073
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2017, FASB issued accounting standards update ASU-2017-09, “Compensation-Stock Compensation” (Topic 718) –Modification Accounting”, to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this ASU are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period for public entities for reporting periods for which financial statements have not yet been issued, and all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company is currently evaluating the impact of the adoption of ASU 2017-09 on the Company’s financial statements. In August 2017, FASB issued accounting standards update ASU-2017-12, “D” (Topic 815) – “Targeted Improvements to Accounting for Hedging Activities”, to require an entity to present the earnings effect of the hedging instrument in the same statement line item in which the earnings effect of the hedged item is reported. The amendments in this update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods with the fiscal years beginning after December 15, 2020. Early adoption is permitted in any interim period after issuance of the update. The Company is currently evaluating the impact of the adoption of ASU 2017-12 on the Company’s financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of intangible assets amortized over their useful lives	Useful Lives 2017 2016 Patents $ 75,487 $ 74,787 Less accumulated amortization 15 years (6,045 ) - $ 69,442 $ 74,787
Schedule of property and equipment	Computer equipment 5 Years Machinery and equipment 10 Years
Schedule of net earnings per share	For the years ended December 31, 2017 2016 Income (Loss) to common shareholders (Numerator) $ (2,785,024 ) $ 199,799 Basic weighted average number of common shares outstanding (Denominator) 35,784,211 22,971,319 Diluted weighted average number of common shares outstanding (Denominator) 35,784,211 39,096,319
Schedule of assets and liabilities measured at fair value on recurring basis	Total (Level 1) (Level 2) (Level 3) Derivative Liability Total Liabilities measured at fair value as of December 31, 2017 $ 5,239,073 $ - $ - $ 5,239,073 Total Liabilities measured at fair value as of December 31, 2016 $ 5,044,897 $ - $ - $ 5,044,897
Schedule of reconciliation of derivative liability	Balance as of January 1, 2016 $ 7,878,599 Fair value of derivative liabilities issued 301,111 Loss on conversion of debt and change in derivative liability (3,134,813 ) Balance as of December 31, 2016 $ 5,044,897 Fair value of derivative liabilities issued 15,840 Gain on conversion of debt and change in derivative liability 173,338 Balance as of December 31, 2017 $ 5,239,073

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock options	2017 2016 Number of Options Weighted average exercise price Number of Options Weighted average exercise price Outstanding as of the beginning of the years 15,975,000 $ 0.23 15,978,333 $ 0.23 Granted - $ - - $ - Exercised - $ - - $ - Expired - $ - (3,333 ) $ 4.05 Outstanding as of the end of the years 15,975,000 $ 0.23 15,975,000 $ 0.23 Exercisable as of the end of the years 15,975,000 $ 0.23 10,183,000 $ 0.21
Schedule of weighted average remaining contractual life of options outstanding	12/31/2017 12/31/2016 Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) Exercisable Price Stock Options Outstanding Stock Options Exercisable Weighted Average Remaining Contractual Life (years) $ 0.40 25,000 25,000 0.16 $ 0.40 25,000 25,000 1.17 $ 0.09 2,450,000 2,450,000 4.23 $ 0.09 2,450,000 2,058,000 5.23 $ 0.26 13,500,000 13,500,000 4.67 $ 0.26 13,500,000 8,100,000 5.70 15,975,000 15,975,000 15,975,000 10,183,000
Schedule of warrants outstanding	2017 2016 Number of Warrants Weighted average exercise price Number of Warrants Weighted average exercise price Outstanding as of the beginning of the years $ 150,000 $ 0.55 $ 245,000 $ 0.97 Granted - - - Exercised - - - Expired (150,000 ) $ 0.55 $ (95,000 ) $ 1.80 Outstanding as of the end of the years $ - $ - $ 150,000 $ 0.55 Exercisable at the end of years $ - $ - $ 150,000 $ 0.55

Convertible Promissory Notes (T

Convertible Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of outstanding convertible promissory notes	Convertible Promissory Notes, net of debt discount $ 2,187,939 Less current portion 396,660 Total long-term liabilities $ 1,791,279
Schedule of maturities of long-term debt	Year Ending December 31, Amount 2019 $ 306,630 2020 730,000 2021 754,649 $ 1,791,279

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative liabilities valuation assumptions	12/31/2017 Risk free interest rate 1.39% - 2.20 % Stock volatility factor 74.0% - 136 % Weighted average expected option life 1 years - 5 years Expected dividend yield None

Deferred Taxes (Tables)

Deferred Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense	2017 2016 Book income (loss) $ (1,114,010 ) $ 79,830 Depreciation 680 (1,590 ) Meals and entertainment 240 160 Non-deductible non-cash charges 879,830 (380,530 ) Valuation Allowance 233,260 302,130 Income tax expense $ - $ -
Schedule of deferred tax assets and liabilities	2017 2016 Deferred tax assets: NOL carryover $ (3,170,060 ) $ (2,947,120 ) R & D credit 91,630 87,480 Depreciation 10,740 10,740 Deferred tax liabilites: Depreciation - - Less Valuation Allowance 3,067,690 2,848,900 Net deferred tax asset $ - $ -

Organization and Line of Busi22

Organization and Line of Business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization and Line of Business (Textual)
Net loss	$ (2,785,024)	$ 199,799
Used cash in operations	(560,483)	(671,864)
Working capital deficiency	5,941,190
Shareholders' deficit	$ (7,654,535)	$ (6,644,200)	$ (8,724,709)

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Patents	$ 75,487	$ 74,787
Less accumulated amortization	6,045	0
Patents, net	$ 69,442	$ 74,787
Patents, Useful Lives	15 years

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2017
Computer equipment [Member]
Property and equipment, Useful lives	5 years
Machinery and equipment [Member]
Property and equipment, Useful lives	10 years

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Details 2) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Income (Loss) to common shareholders (Numerator)	$ (2,785,024)	$ 199,799
Basic weighted average number of common shares outstanding (Denominator)	35,784,211	22,971,319
Diluted weighted average number of common shares outstanding (Denominator)	35,784,211	39,096,319

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Details 3) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Derivative Liability
Total Liabilities measured at fair value	$ 5,239,073	$ 5,044,897
(Level 1) [Member]
Derivative Liability
Total Liabilities measured at fair value
(Level 2) [Member]
Derivative Liability
Total Liabilities measured at fair value
(Level 3) [Member]
Derivative Liability
Total Liabilities measured at fair value	$ 5,239,073	$ 5,044,897

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details 4) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of reconciliation of derivative liability
Balance, Beginning	$ 5,044,897
Balance, Ending	5,239,073	$ 5,044,897
Level 3 [Member]
Schedule of reconciliation of derivative liability
Balance, Beginning	5,044,897	7,878,599
Fair value of derivative liabilities issued	15,840	301,111
Loss on conversion of debt and change in derivative liability		(3,134,813)
Gain on conversion of debt and change in derivative liability	173,338
Balance, Ending	$ 5,239,073	$ 5,044,897

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Textual) - USD ($)	Sep. 02, 2015	Mar. 24, 2015	Dec. 31, 2017	Dec. 31, 2016
Summary of Significant Accounting Policies (Textual)
Number of options granted
Exercise price
Stock options vesting rights			The options will vest 1/25 on monthly basis, starting April 24, 2015 and October 1, 2015, respectively.
Expiration period			7 years
Outstanding warrants
Research and development costs			$ 176,306	$ 226,881
Recognized amortization expense			6,045	0
Depreciation expense			$ 3,323	3,085
Tax settlement, percentage			50%
Convertible debt [Member]
Summary of Significant Accounting Policies (Textual)
Antidilutive securities excluded from computation of earnings per share amount, value			$ 2,193,630	$ 1,800,000
Warrants [Member]
Summary of Significant Accounting Policies (Textual)
Outstanding warrants				150,000
Stock options [Member]
Summary of Significant Accounting Policies (Textual)
Number of options granted	13,500,000	2,450,000
Exercise price	$ 0.26	$ 0.09
Antidilutive securities excluded from computation of earnings per share, amount			15,975,000
Outstanding stock options				1,650,000

Capital Stock (Details)

Capital Stock (Details) - Convertible promissory notes [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Capital Stock (Textual)
Common stock issued	11,965,646	8,437,636
Aggregate fair value loss	$ 408,144
Common stock conversion price per share		$ 0.01333
Amount of debt conversion	78,370	$ 84,500
Accrued interest	$ 22,939	$ 17,934
Common stock price per share		$ 0.00847
Conversion related party [Member]
Capital Stock (Textual)
Common stock issued		3,085,816
Amount of debt conversion		$ 185,000
Accrued interest		$ 21,507
Maximum [Member]
Capital Stock (Textual)
Common stock conversion price per share	$ 0.0549
Maximum [Member] | Conversion related party [Member]
Capital Stock (Textual)
Common stock conversion price per share		$ 0.115
Minimum [Member]
Capital Stock (Textual)
Common stock conversion price per share	$ 0.0350
Minimum [Member] | Conversion related party [Member]
Capital Stock (Textual)
Common stock conversion price per share		$ 0.056

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Options
Outstanding as of the beginning of the years	15,975,000	15,978,333
Granted
Exercised
Expired		(3,333)
Outstanding as of the end of the years	15,975,000	15,975,000
Exercisable as of the end of the years	15,975,000	10,183,000
Weighted average exercise price
Outstanding as of the beginning of the years	$ 0.23	$ 0.23
Granted
Exercised
Expired		4.05
Outstanding as of the end of the years	0.23	0.23
Exercisable as of the end of the years	$ 0.23	$ 0.21

Stock Options and Warrants (D31

Stock Options and Warrants (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of weighted average remaining contractual life of options outstanding
Stock Options Outstanding	15,975,000	15,975,000
Stock Options Exercisable	15,975,000	10,183,000
0.40 [Member]
Schedule of weighted average remaining contractual life of options outstanding
Exercisable Price	$ 0.40	$ 0.40
Stock Options Outstanding	25,000	25,000
Stock Options Exercisable	25,000	25,000
Weighted Average Remaining Contractual Life (years)	1 month 27 days	1 year 2 months 1 day
0.09 [Member]
Schedule of weighted average remaining contractual life of options outstanding
Exercisable Price	$ 0.09	$ 0.09
Stock Options Outstanding	2,450,000	2,450,000
Stock Options Exercisable	2,450,000	2,058,000
Weighted Average Remaining Contractual Life (years)	4 years 2 months 23 days	5 years 2 months 23 days
0.26 [Member]
Schedule of weighted average remaining contractual life of options outstanding
Exercisable Price	$ 0.26	$ 0.26
Stock Options Outstanding	13,500,000	13,500,000
Stock Options Exercisable	13,500,000	8,100,000
Weighted Average Remaining Contractual Life (years)	4 years 8 months 2 days	5 years 8 months 12 days

Stock Options and Warrants (D32

Stock Options and Warrants (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Warrants
Outstanding as of the beginning of the years	150,000	245,000
Granted
Exercised
Expired	(150,000)	(95,000)
Outstanding as of the end of the years		150,000
Exercisable at the end of years		150,000
Weighted average exercise price
Outstanding as of the beginning of the years	$ 0.55	$ 0.97
Granted
Exercised
Expired	0.55	1.80
Outstanding as of the end of the years		0.55
Exercisable at the end of years		$ 0.55

Stock Options and Warrants (D33

Stock Options and Warrants (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock Options and Warrants (Textual)
Stock-based compensation expense	$ 1,265,236	$ 1,571,769
Intrinsic value of options outstanding
Warrants outstanding
Expiration date	Oct. 31, 2017
Purchase warrants	150,000

Convertible Promissory Notes (D

Convertible Promissory Notes (Details)	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
Convertible Promissory Notes, net of debt discount	$ 2,187,939
Less current portion	396,660
Total long-term liabilities	$ 1,791,279

Convertible Promissory Notes 35

Convertible Promissory Notes (Details 1)	Dec. 31, 2017USD ($)
Year Ending December 31,
2,019	$ 306,630
2,020	730,000
2,021	754,649
Total long-term debt	$ 1,791,279

Convertible Promissory Notes 36

Convertible Promissory Notes (Details Textual) - USD ($)	Mar. 20, 2017	Apr. 05, 2016	Oct. 01, 2015	May 02, 2014	Jan. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Convertible Promissory Notes (Textual)
Tranche amount received						$ 472,000	$ 685,000
Amortization of debt discount recognized as interest expense						146,279	$ 443,979
Convertible promissory notes						2,193,630
Debt discount						5,691
Net balance						2,187,939
10% Unsecured convertible note [Member]
Convertible Promissory Notes (Textual)
Unsecured convertible note principal amount				$ 500,000
Convertible promissory note interest, percentage				10.00%
Tranche amount received				$ 50,000
Additional tranche amount received				450,000
Aggregate principal amount				$ 500,000				$ 467,500
Principal amount converted						$ 306,630
Shares issued upon conversion of debt						11,965,646
Value issued upon conversion of debt						$ 78,370
Accrued interest						$ 22,939
Debt instrument, description						Each tranche matures eighteen (18) months from the effective date of each tranche, which was extended on January 12, 2016 to sixty (60) months, with maturity dates ranging from June 12, 2019 to December 21, 2019.
Debt conversion, description						The May Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. The fair value of the May Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche.
10% Unsecured convertible note one [Member]
Convertible Promissory Notes (Textual)
Unsecured convertible note principal amount					$ 500,000
Convertible promissory note interest, percentage					10.00%
Tranche amount received					$ 50,000
Additional tranche amount received					$ 450,000
Aggregate principal amount						$ 500,000
Debt instrument, description						Each tranche matured eighteen (18) months from the effective date of each tranche, which was extended on January 12, 2016 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from January 29, 2020 to August 25, 2020.
Debt conversion, description						The January Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.15 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the January Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the January Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche.
Amortization of debt discount recognized as interest expense						$ 25,898
10% Unsecured convertible note two [Member]
Convertible Promissory Notes (Textual)
Unsecured convertible note principal amount			$ 500,000
Convertible promissory note interest, percentage			10.00%
Tranche amount received			$ 90,000
Additional tranche amount received			$ 395,000
Aggregate principal amount						$ 485,000
Debt instrument, description						Each tranche matures twelve (12) months from the effective date of each tranche, which was extended on October 13, 2016 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from October 1, 2020 to March 9, 2021.
Debt conversion, description						The October Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the October Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the October Note has been determined by using the Binomial lattice formula with an expected life of twelve (12) months.
Amortization of debt discount recognized as interest expense						$ 9,912
10% Unsecured convertible note three [Member]
Convertible Promissory Notes (Textual)
Unsecured convertible note principal amount		$ 500,000
Convertible promissory note interest, percentage		10.00%
Tranche amount received		$ 48,000
Additional tranche amount received		$ 452,000
Aggregate principal amount						$ 500,000
Debt instrument, description						Each tranche matures twelve (12) months from the effective date of each tranche through November 15, 2017.
Debt conversion, description						The April Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the April Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the April Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months.
Amortization of debt discount recognized as interest expense						$ 104,524
10% Unsecured convertible note four [Member]
Convertible Promissory Notes (Textual)
Unsecured convertible note principal amount	$ 500,000
Convertible promissory note interest, percentage	10.00%
Tranche amount received	$ 25,000
Additional tranche amount received						377,000
Aggregate principal amount						$ 402,000
Debt instrument, description						Each tranche matures twelve (12) months from the effective date of each tranche, with an extension of sixty (60) months from each tranche.
Debt conversion, description						The March Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the March Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. The fair value of the March Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months.
Amortization of debt discount recognized as interest expense						$ 5,945

Derivative Liabilities (Details

Derivative Liabilities (Details)	12 Months Ended
	Dec. 31, 2017
Expected dividend yield
Minimum [Member]
Risk free interest rate	1.39%
Stock volatility factor	74.00%
Weighted average expected option life	1 year
Maximum [Member]
Risk free interest rate	2.20%
Stock volatility factor	136.00%
Weighted average expected option life	5 years

Derivative Liabilities (Detai38

Derivative Liabilities (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Derivative Liabilities (Textual)
Fair value of the derivative liability	$ 5,239,073	$ 5,044,897
Convertible notes [Member]
Derivative Liabilities (Textual)
Fair value of the conversion feature	15,840
Amount of debt conversion	78,370
Conversion of debt, amount	586,481
Accrued interest	$ 22,939

Deferred Taxes (Details)

Deferred Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Book income (loss)	$ (1,114,010)	$ 79,830
Depreciation	680	(1,590)
Meals and entertainment	240	160
Non-deductible non-cash charges	879,830	(380,530)
Valuation Allowance	233,260	302,130
Income tax expense

Deferred Taxes (Details 1)

Deferred Taxes (Details 1) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
NOL carryover	$ (3,170,060)	$ (2,947,120)
R & D credit	91,630	87,480
Depreciation	10,740	10,740
Deferred tax liabilities:
Depreciation
Less Valuation Allowance	3,067,690	2,848,900
Net deferred tax asset

Deferred Taxes (Details Textual

Deferred Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)
Deferred Taxes (Textual)
Operating loss carry-forwards	$ 7,925,000
Operating loss carry-forwards expiration, term	Which expires 20 years after the NOL year.

Commitment and Contingencies (D

Commitment and Contingencies (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
Commitment and Contingencies (Textual)
Description of commitment	On August 24, 2017, the Company extended its contract for a period of September 12, 2017 through September 11, 2018.
Commitment total cost	$ 159,610

Subsequent Events (Details)

Subsequent Events (Details)	Jan. 31, 2018USD ($)Tranche / Numbershares	Feb. 28, 2018USD ($)Tranche / Numbershares	Feb. 26, 2018USD ($)	Mar. 20, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Subsequent Events (Textual)
Tranches amount receivable					$ 472,000	$ 685,000
Subsequent Events [Member]
Subsequent Events (Textual)
Common stock issued | shares	5,023,283	5,023,283
Principal amount	$ 28,190	$ 28,190
Accrued interest	9,734	9,734
Securities Purchase Agreement [Member]
Subsequent Events (Textual)
Principal amount				$ 500,000
Debt conversion, description				The March Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded on any trade day after the effective date or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock.
Securities Purchase Agreement [Member] | Subsequent Events [Member]
Subsequent Events (Textual)
Tranches amount receivable	$ 98,000	$ 98,000
Number of tranches | Tranche / Number	2	2
10% unsecured convertible note [Member] | Subsequent Events [Member]
Subsequent Events (Textual)
Tranches amount receivable			$ 15,000
Principal amount			$ 500,000
Debt conversion, description			The February Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.03 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded on any trade day after the effective date or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock.